Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 637

1.

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review.

van der Wall SJ, van der Pol LM, Ende-Verhaar YM, Cannegieter SC, Schulman S, Prandoni P, Rodger M, Huisman MV, Klok FA.

Eur Respir Rev. 2018 Nov 28;27(150). pii: 180094. doi: 10.1183/16000617.0094-2018. Print 2018 Dec 31. Review.

2.

Sustained inflations and avoiding mechanical ventilation to prevent death or bronchopulmonary dysplasia: a meta-analysis.

Fischer HS, Schmölzer GM, Cheung PY, Bührer C.

Eur Respir Rev. 2018 Nov 28;27(150). pii: 180083. doi: 10.1183/16000617.0083-2018. Print 2018 Dec 31. Review.

3.

"Cardiovascular disease and COPD: dangerous liaisons." Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057.

[No authors listed]

Eur Respir Rev. 2018 Nov 21;27(150). pii: 185057. doi: 10.1183/16000617.5057-2018. Print 2018 Dec 31. No abstract available.

4.

Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit.

Huapaya JA, Wilfong EM, Harden CT, Brower RG, Danoff SK.

Eur Respir Rev. 2018 Nov 21;27(150). pii: 180061. doi: 10.1183/16000617.0061-2018. Print 2018 Dec 31. Review.

5.

Current opinions for the management of asthma associated with ear, nose and throat comorbidities.

Tiotiu A, Plavec D, Novakova S, Mihaicuta S, Novakova P, Labor M, Bikov A.

Eur Respir Rev. 2018 Nov 21;27(150). pii: 180056. doi: 10.1183/16000617.0056-2018. Print 2018 Dec 31. Review.

6.

Cardiovascular disease and COPD: dangerous liaisons?

Rabe KF, Hurst JR, Suissa S.

Eur Respir Rev. 2018 Oct 3;27(149). pii: 180057. doi: 10.1183/16000617.0057-2018. Print 2018 Sep 30. Review. Erratum in: Eur Respir Rev. 2018 Nov 21;27(150):.

7.

Randomised controlled trials and real-life studies: two answers for one question.

Harari S.

Eur Respir Rev. 2018 Sep 26;27(149). pii: 180080. doi: 10.1183/16000617.0080-2018. Print 2018 Sep 30. No abstract available.

8.

Cadmium lung adsorption, citrullination and an enhanced risk of COPD.

Hutchinson D.

Eur Respir Rev. 2018 Sep 26;27(149). pii: 180054. doi: 10.1183/16000617.0054-2018. Print 2018 Sep 30. No abstract available.

9.

Pulmonary hypertension associated with neurofibromatosis type 1.

Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180053. doi: 10.1183/16000617.0053-2018. Print 2018 Sep 30.

10.

How long is too long? A scoping review of health system delays in lung cancer.

Malalasekera A, Nahm S, Blinman PL, Kao SC, Dhillon HM, Vardy JL.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180045. doi: 10.1183/16000617.0045-2018. Print 2018 Sep 30. Review.

11.

The broad spectrum of lung diseases in primary antibody deficiencies.

Cinetto F, Scarpa R, Rattazzi M, Agostini C.

Eur Respir Rev. 2018 Aug 29;27(149). pii: 180019. doi: 10.1183/16000617.0019-2018. Print 2018 Sep 30. Review.

12.

Precision medicine in COPD: where are we and where do we need to go?

Sidhaye VK, Nishida K, Martinez FJ.

Eur Respir Rev. 2018 Aug 1;27(149). pii: 180022. doi: 10.1183/16000617.0022-2018. Print 2018 Sep 30.

13.

Noninvasive ventilation in acute respiratory failure: which recipe for success?

Scala R, Pisani L.

Eur Respir Rev. 2018 Jul 11;27(149). pii: 180029. doi: 10.1183/16000617.0029-2018. Print 2018 Sep 30.

14.

Bronchiectasis: a case-based approach to investigation and management.

Contarini M, Finch S, Chalmers JD.

Eur Respir Rev. 2018 Jul 11;27(149). pii: 180016. doi: 10.1183/16000617.0016-2018. Print 2018 Sep 30. Review.

15.

Systematic review of drug effects in humans and models with surfactant-processing disease.

Klay D, Hoffman TW, Harmsze AM, Grutters JC, van Moorsel CHM.

Eur Respir Rev. 2018 Jul 11;27(149). pii: 170135. doi: 10.1183/16000617.0135-2017. Print 2018 Sep 30. Review.

16.

Interstitial pneumonia with autoimmune features: a new classification still on the move.

Cavagna L, Gonzalez Gay MA, Allanore Y, Matucci-Cerinic M.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180047. doi: 10.1183/16000617.0047-2018. Print 2018 Jun 30. No abstract available.

17.

Cell-matrix interactions in lung disease and regeneration: ERS Lung Science Conference 2018 report.

Meiners S, Lloyd C, Chambers RC.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180040. doi: 10.1183/16000617.0040-2018. Print 2018 Jun 30. No abstract available.

18.

Matrix abnormalities in pulmonary fibrosis.

Upagupta C, Shimbori C, Alsilmi R, Kolb M.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180033. doi: 10.1183/16000617.0033-2018. Print 2018 Jun 30. Review.

19.

The consequence of matrix dysfunction on lung immunity and the microbiome in COPD.

Hussell T, Lui S, Jagger C, Morgan D, Brand O.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180032. doi: 10.1183/16000617.0032-2018. Print 2018 Jun 30.

20.

How bacteria hack the matrix and dodge the bullets of immunity.

Paulsson M, Riesbeck K.

Eur Respir Rev. 2018 Jun 27;27(148). pii: 180018. doi: 10.1183/16000617.0018-2018. Print 2018 Jun 30. Review.

Supplemental Content

Loading ...
Support Center